In his most recent blog, Clay Siegall wrote about the proposal by the American government to reduce funding for the various state agencies including the Environmental Protection Agency. This may affect the agency’s capacity to enforce the various federal water standards.
In another blog, Siegall talks about an interesting finding by researchers about dreams. Researchers have found a pattern of brain activity that can be used to tell when and what one is dreaming about. One of the researchers says there is a part of the brain that seems to be very active.
To carry out the research, people were woken open in the middle of the night and asked if they had dreamed and what the dream was. The researchers then used high-density electroencephalography to analyze the brain activity patterns.
As the CEO of Seattle Genetics, what is Clay Siegall’s main responsibility?
Clay B. Siegall, Ph.D. is a scientist by training, and in 1998, he co-founded Seattle Genetics. He was the company’s Executive Vice President between 1998 and 2000. He was also the Chief Scientific Officer until 2002. He has been the company’s CEO and President since November 2002 and June 2000 respectively.
He started Seattle Genetics to not only enhance scientific research, intensive research, and drug development but also to assist patients. As the CEO, he has helped the company become a leader in the development of Antibody-Drug Conjugates (ADCs). He has helped in the approval of ADCETRIS® (brentuximab vedotin) by FDA in 2011.
In his leadership, the company has entered into various licenses with companies like Genentech (Roche) and GlaxoSmithKline among others for their ADC technology. This has seen the company generate a lot of revenue.
The Role of Clay Siegall in the Cancer Research Community
Since starting his profession in biomedical studies, Dr. Siegall has been concerned with helping cancer patients improve their lives. The effort by Seattle Genetics has seen their stock price triple in about five years.
After earning his Ph.D. in Genetics, he began his career in research at the Bristol-Myers Squibb Pharmaceutical Research Institute where he served as a Senior Research Investigator. He was later promoted and was able to assist in the launching of Seattle Genetics.
At Seattle Genetics, he has helped in the development of the first ADCs. ADCETRIS® is now available to many cancer patients around the world.